Evan Braunstein is an Oncology physician affiliated with Incyte. OpenAlex indexes 93 publications with 3,818 citations (h-index 24).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
401 North Broadway
Room 1363
Baltimore, MD 212311146
Telephone
410-955-8893Provider last certified this registry record 3 Sept 2021.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20221 payment
- Merck Sharp & Dohme CorporationProgram year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Interferon alfa-2b100%Besremi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2018–2021 per NIH RePORTER. The latest:
- Investigation of ERBB2 and ERBB3 in hematopoiesis and predisposition to hematologic disease
Johns Hopkins University
FY2021$172,530K08HL138142 - Investigation of ERBB2 and ERBB3 in hematopoiesis and predisposition to hematologic disease
Johns Hopkins University
FY2020$172,530K08HL138142 - Investigation of ERBB2 and ERBB3 in hematopoiesis and predisposition to hematologic disease
Johns Hopkins University
FY2019$172,530K08HL138142
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Genetic and epigenetic dysregulation of CR1 is associated with catastrophic antiphospholipid syndrome
Annals of the Rheumatic Diseases
2025 - Genetic justification of<scp>COVID</scp>‐19 patient outcomes using<scp>DERGA</scp>, a novel data ensemble refinement greedy algorithm
Journal of Cellular and Molecular Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Thomas Karasic, MD
Incyte
Sadhna Shankar, MD, MPH
Incyte
Gerard Kennealey, MD
Incyte
Mark Cornfeld, MD
Incyte
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”